This safety feature means GLP-1 medications rarely cause low blood sugar episodes on their own, making them a lower-risk option for people with type 2 diabetes or prediabetes
For example, finerenone trials such as FIDELIO-DKD and FIGARO-DKD required baseline serum potassium 4.8 mmol/L, whereas the more recent FINEARTS-HF trial allowed inclusion of patients with potassium up to 5.0 mmol/L (Fig
Imagine losing 2030% of your body weightwithout extreme diets or hours in the gym
It's a critical, non-negotiable element of the coverage puzzle
There is a strong interest in developing obesity treatments based on glucagon-like peptide-1 (GLP-1) agonists, which have proved to limit morbidity and mortality in type 2 diabetes
That history matters, because it trains you to expect fast feedback and to panic the moment the feedback slows down